Benjamin Landry Sells 2,500 Shares of Health Catalyst, Inc. (NASDAQ:HCAT) Stock

Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) General Counsel Benjamin Landry sold 2,500 shares of the firm's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $7.52, for a total value of $18,800.00. Following the transaction, the general counsel now owns 72,250 shares of the company's stock, valued at $543,320. The trade was a 3.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Benjamin Landry also recently made the following trade(s):

• On Friday, December 6th, Benjamin Landry sold 19,268 shares of Health Catalyst stock. The stock was sold at an average price of $8.32, for a total value of $160,309.76.

Health Catalyst Stock Performance

Shares of HCAT stock traded down $0.47 during trading hours on Friday, reaching $6.89. 477,428 shares of the company traded hands, compared to its average volume of 547,021. Health Catalyst, Inc. has a 12-month low of $5.42 and a 12-month high of $11.41. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The company has a market cap of $419.24 million, a P/E ratio of -5.10 and a beta of 1.36. The firm has a 50-day moving average price of $7.79 and a 200 day moving average price of $7.52.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company had revenue of $76.40 million for the quarter, compared to analysts' expectations of $76.27 million. During the same period in the previous year, the firm earned ($0.22) earnings per share. The firm's quarterly revenue was up 3.5% on a year-over-year basis. As a group, sell-side analysts predict that Health Catalyst, Inc. will post -0.33 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Piper Sandler reiterated an "overweight" rating and issued a $12.00 price objective (up from $11.00) on shares of Health Catalyst in a report on Tuesday, November 26th. Royal Bank of Canada lifted their price objective on Health Catalyst from $8.00 to $9.00 and gave the stock a "sector perform" rating in a report on Thursday, November 7th. KeyCorp upgraded Health Catalyst from a "sector weight" rating to an "overweight" rating and set a $9.00 price objective for the company in a report on Wednesday. Evercore ISI boosted their price target on Health Catalyst from $8.00 to $10.00 and gave the company an "outperform" rating in a research note on Tuesday, October 8th. Finally, Citigroup cut their price target on Health Catalyst from $10.50 to $10.00 and set a "buy" rating for the company in a research note on Friday. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, Health Catalyst presently has a consensus rating of "Moderate Buy" and an average price target of $11.45.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Franklin Resources Inc. raised its holdings in shares of Health Catalyst by 5.8% during the 3rd quarter. Franklin Resources Inc. now owns 104,141 shares of the company's stock worth $857,000 after acquiring an additional 5,687 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Health Catalyst by 4.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company's stock worth $11,749,000 after acquiring an additional 66,896 shares in the last quarter. Zacks Investment Management raised its holdings in shares of Health Catalyst by 6.7% during the 3rd quarter. Zacks Investment Management now owns 296,121 shares of the company's stock worth $2,410,000 after acquiring an additional 18,677 shares in the last quarter. State Street Corp raised its holdings in shares of Health Catalyst by 2.5% during the 3rd quarter. State Street Corp now owns 1,163,754 shares of the company's stock worth $9,473,000 after acquiring an additional 28,251 shares in the last quarter. Finally, Quadrature Capital Ltd purchased a new stake in shares of Health Catalyst during the 3rd quarter worth approximately $84,000. 85.00% of the stock is owned by hedge funds and other institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.